Clinical Trials Logo

Advanced Solid Tumours clinical trials

View clinical trials related to Advanced Solid Tumours.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06380816 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells. The four main aims of the clinical trial are to find out: 1. The best dose of UCB4594 that can be given safely to participants in the trial. 2. What the side effects of UCB4594 are and how they can be managed. 3. What happens to UCB4594 inside the body and how it affects cancer cells. 4. Whether UCB4594 can cause cancer to shrink.

NCT ID: NCT05537051 Not yet recruiting - Clinical trials for Advanced Solid Tumours

A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours

Start date: October 30, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this research is to assess the safety, tolerability and effectiveness of PM1021 Monotherapy and PM1021 in Combination with PM8001 in Patients with Advanced Solid Tumours. In this study, up to 30 patients will be enrolled in Australia only. Advanced solid cancers are associated with poor prognosis and pose a significant challenge for treatment strategies. Effective treatments for advanced metastatic malignancies that have failed available standard of care treatment represent a major unmet medical need. Biotheus Inc. is developing PM1021, a monoclonal anti-T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) antibody (IgG1) and PM8001 (a PD-L1/TGF-beta bispecific Fc fusion protein) as treatment for advanced solid tumours.

NCT ID: NCT05154604 Not yet recruiting - Clinical trials for Advanced Solid Tumours

A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

Start date: December 31, 2021
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of SHR-A1921